Clinical Trial Update: Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating bafetinib (INNO-406) in patients with hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Bafetinib (INNO-406) (bafetinib)

Snippet

Sponsor: CytRx | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED